Trial
NCT05061251
Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma
Early Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Bayer
Condition
Glioma
Intervention
BAY 2402234
Why stopped
Drug availability
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-11